{"id":390894,"date":"2017-10-04T00:00:00","date_gmt":"2017-10-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2017-biopharma-type-1-diabetes-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-03-31T10:49:49","modified_gmt":"2026-03-31T10:49:49","slug":"dlsfmd0009-2017-biopharma-type-1-diabetes-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2017-biopharma-type-1-diabetes-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Type 1 Diabetes | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (<abbr title=\"type 1 diabetes\">T1D<\/abbr>) space\u00a0as the number of treatment options continues to grow. Existing agents fail to provide sustained and intrinsic control of\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>, and none address the autoimmune component of\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>\u2019s etiology. While late-stage pipeline therapies in development represent drug classes already on the market (e.g.,\u00a0<abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr>\u00a0inhibitors), several early-stage pipeline therapies present genuine novel mechanisms of action. There is a shifting emphasis on the types of therapies in development for\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>, with significant interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors. The launch of biosimilar insulins\u00a0is having a profound effect on the\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>\u00a0market across the G7, and we are witnessing an intricate interplay of physician and payer attitudes to this new treatment option.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li><strong>What<\/strong><strong>\u00a0clinical role will oral therapies, regenerative\u00a0approaches, and immunological approaches\u00a0play in the evolving\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>\u00a0treatment landscape?<\/strong><\/li>\n<li><strong>What will be the market impact of Boehringer Ingelheim\/Eli Lilly\u2019s Abasaglar and other biosimilars? How resistant are physicians to payer pressure regarding switching patients to biosimilars?<\/strong><\/li>\n<li><strong>How will endocrinologists differentiate between the emerging therapies, and which will enjoy the greatest clinical and commercial success in an increasingly stringent regulatory environment?<\/strong><\/li>\n<li><strong>What can entrenched\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>\u00a0players do to further protect their franchises from biosimilar and novel agent competition?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope<\/strong><\/p>\n<p><strong>Markets covered:\u00a0<\/strong>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>20 country-specific interviews with thought-leaders and endocrinologists. Patient shares surveyed in all regions.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed prevalence; 3 drug-treated subpopulations modeled\u2014 adult, adolescent, and child.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase II: 30+\u00a0drugs; Phase III: 7\u00a0drugs; preregistration: 2\u00a0drugs. Coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Market forecast features:<\/strong>\u00a0Using a proprietary model, we forecast population sizes and\u00a0<abbr title=\"type 1 diabetes\">T1D<\/abbr>\u00a0drug sales for rolled-up adult, adolescent, and child patient segments through 2026.<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Novo Nordisk, Sanofi, Eli Lilly,\u00a0Merck, Boehringer\u00a0Ingelheim, Samsung Bioepis, Mylan, Biocon, Astellas, Janssen, Bristol-Myers Squibb, AstraZeneca, Lexicon, Sanofi<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Lantus, Levemir, Toujeo, Tresiba, Abasaglar,\u00a0NovoLog, Humalog, Fiasp, Admelog, Ryzodeg,\u00a0Jardiance, Farxiga, Invokana, Suglat,\u00a0sotagliflozin.<\/p>\n","protected":false},"template":"","class_list":["post-390894","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390894\/revisions"}],"predecessor-version":[{"id":394018,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390894\/revisions\/394018"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}